Reported Reactions

Devices › Immunoassay method, troponin subunit

Device brand name · Troponin immunoassay

Advia Centaur Troponin Ultra Assay: medical device reports filed with FDA

161 reports name it, 2007–2014. Manufacturer given most often on reports: Siemens Healthcare Diagnostics. Product code MMI.

161
device reports naming the brand
0% of all MAUDE reports · about 9 a year
0
reports, 12 months to August 2026
0 in the 12 months before
37.3%
classified as malfunction
87.4% across the product code
0%
classified as death, as reported
0 reports · not verified by FDA

161 medical device reports received by FDA name the brand "Advia Centaur Troponin Ultra Assay" (troponin immunoassay); the manufacturer given most often on reports is Siemens Healthcare Diagnostics; received from October 2007 to October 2014. Brand names are as the reporter or manufacturer wrote them, so one product can appear under several spellings.

0 reports arrived in the 12 months to August 2026, and none in the 12 months before. FDA releases MAUDE data monthly; reports can arrive months after an event, so the newest months grow in later releases. The event types recorded are other (60.2%), malfunction (37.3%) and injury (0.6%); across all immunoassay method, troponin subunit reports (product code MMI) death is recorded in 0.1% and malfunction in 87.4%. Event type is the reporter's classification of the report, not a verified outcome.

The device problems coded most often are false positive result (41.6%), high test results (22.4%) and incorrect or inadequate test results (16.8%). The patient problems coded most often are hospitalization required, therapy/non-surgical treatment, unncessary and therapy/non-surgical treatment, additional. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data."

Reports by month, five years

No report naming Advia Centaur Troponin Ultra Assay was received in the five years to August 2026; the latest was received in October 2014.

By year received

030602007: 520072008: 6020082009: 2220092010: 2120102011: 920112012: 3120122013: 1020132014: 32014

Event type and report source

Event type, as classified on the report

Death0%0
Injury0.6%1
Malfunction37.3%60
Other60.2%97
Not given1.9%3

Who filed the report

Manufacturer report100%161
Voluntary report0%0
User facility report0%0
Distributor report0%0
Not given0%0

Grey bar: all 18,167 reports carrying product code MMI. Event type is the filer's classification and is not verified by FDA.

Device problems coded

Device problem (FDA code)ReportsShareShare across product code
False positive result6741.6%13.3%
High test results3622.4%60.3%
Incorrect or inadequate test results2716.8%13.6%
False negative result21.2%2.4%
Low test results21.2%4.6%
Failure to calibrate10.6%0.1%

FDA's device problem codes as entered on the report; one report can carry several. Generic codes such as "no apparent adverse event" are left out.

Patient problems coded

Patient problem (FDA code)ReportsShare
Hospitalization required74.3%
Therapy/non-surgical treatment, unncessary31.9%
Therapy/non-surgical treatment, additional21.2%
Treatment with medication(s)21.2%
Surgical procedure aborted/stopped10.6%
Therapy/non-surgical treatment, aborted/stopped10.6%

Patient problem codes are present mainly in reports filed since 2019 and are often blank.

In context

MeasureAdvia Centaur Troponin Ultra AssayProduct code MMIAll MAUDE reports
Reports16118,16726,136,888
Share of that pool—0.9%0%
Classified as death, per 1,000 reports019
Classified as injury0.6%8.6%36.2%
Classified as malfunction37.3%87.4%62.3%
Filed by the manufacturer100%99.6%94.9%

Shares are of reports, not of devices in use. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data."

Other brands with product code MMI

BrandReportsLatest 12 monthsClassified as death
Access 2 Immunoassay System4,71900%
I-Stat Troponin Ctni Cartridge1,332280%
Dimension Clinical Chemistry System1,89500.2%
ARCHITECT STAT Troponin-I975250.3%
VITROS Immunodiagnostic Products Troponin I ES Reagent Pack892520%
UniCel DxC 600i SYNCHRON Access Clinical System2,975130%
Elecsys Troponin T hs6701360%
Access Accutni+3 Reagent60040%
ARCHITECT STAT High Sensitive Troponin-I502590%
Alinity i STAT High Sensitive Troponin-I Reagent Kit4521470%
Unicel Dxi 800 Access Immunoassay System3,13300%
Atellica IM High-Sensitivity Troponin I (TnIH)372460%
Access Accutni28100%
Architect Stat Troponin-I Reagent Kit24900%
Atellica Im High Sensitivity Troponin I Tnih Assay22200%

Ordered by report count for navigation only. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data." FDA also states that "common products may have a higher number of adverse events due to the higher total number of people using the product."

Questions about Advia Centaur Troponin Ultra Assay reports

How many FDA reports name Advia Centaur Troponin Ultra Assay?

161 medical device reports in the openFDA MAUDE release of 28 Sep 2026, covering reports received through August 2026; 0 in the latest 12 months.

What kinds of events are reported?

other (60.2%), malfunction (37.3%) and injury (0.6%). "Event type" is how the report was classified when filed: death, injury, malfunction or other.

What device problems are coded?

false positive result (41.6%), high test results (22.4%), incorrect or inadequate test results (16.8%), false negative result (1.2%) and low test results (1.2%). These are FDA's device problem codes as entered on the report.

Who files these reports?

manufacturer reports (100%). Manufacturers and user facilities are required to report; voluntary reports come from health professionals and the public.

Do these reports show that Advia Centaur Troponin Ultra Assay was at fault?

No. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data." FDA adds that "a causal relationship cannot be established between product and reactions listed in a report."

How do I report a problem with a medical device?

Through FDA MedWatch (Form FDA 3500 for health professionals and consumers), or to the manufacturer. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Device Adverse Event (MAUDE) bulk export released 28 Sep 2026, which holds reports FDA received through 31 Aug 2026. Brand, generic and manufacturer names are as written on the reports; product code names come from FDA's device classification. A report counts here when any device it lists carries this brand name after punctuation and capitalisation are normalised. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.